The State University of New York’s Blog, Big Ideas, recently published a post featuring highlighting the Long Island Bioscience Hub and how it is working with federal support to transform biomedical research into next-generation medical solutions. Read the post here.
WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2024-12-05 11:35:07
[post_modified_gmt] => 2024-12-05 16:35:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 2499
[post_author] => 4
[post_date] => 2016-11-30 00:57:50
[post_date_gmt] => 2016-11-30 00:57:50
[post_content] => Third round of grants awarded for the development of commercially promising biomedical innovations
The Center for Biotechnology at Stony Brook University, on behalf of the Long Island Bioscience Hub (LIBH), announced the recipients of the third round of funded projects under the Hub’s technology development and commercialization initiative. Funding for ten projects totaling $550,000 has been awarded to applicants from the Hub’s partner institutions. Partner institutions include Stony Brook University, Cold Spring Harbor Laboratory, Brookhaven National Laboratory, and the Feinstein Institute for Medical Research at Northwell Health. Eighteen months after its establishment, the LIBH has already awarded more than $2M to faculty innovators.
The technology development awards made available by the LIBH are specifically aimed at growing a pipeline of commercially promising biomedical technologies that can be out-licensed for further development or serve as the foundation for new company formations in the region. There are two tiers of funding, each with the goal of accelerating technology development to reach a critical development inflection point. Feasibility awards ($50,000) are designed to rapidly test the feasibility of new ideas in a “fail-fast-or-proceed” format, or to add value to existing intellectual property leading to new market applications. Proof-of-Concept Awards ($100,000) provide targeted, milestone driven support for further development, testing, and analysis of existing intellectual property.
A wide range of disciplines are represented in the project awards this cycle including radiology, quantitative biology, biomedical engineering, chemistry, neurosurgery and cancer research. Nine Feasibility awards and one Proof of Concepts award have been funded this cycle. Projects awarded funding in this round include the development of radiotracers for use with PET scans to detect bacterial infections, specifically infective endocarditis (IE); a non-immune-based drug targeting amyloid ß-protein (Aß) for the treatment of mild Alzheimer's disease; DNA nano-carrier platform technology for targeted anti-thrombotic drug delivery in prosthetic heart valve and mechanical circulatory support patients; A medical device utilizing electrical and software engineering in order to detect congenital heart disease in newborn children, and profiling the human immune system through machine learning and bioinformatics. The full list of funded projects can be found on the LIBH webpage.
“The latest announcement of funded project for the LIBH demonstrates the volume of innovation housed within partner institutes that is primed to be moved out of the academic lab and into the commercial sector in order to help patients” said Clinton T. Rubin, Ph.D., Distinguished Professor, Chair, Department of Biomedical Engineering, and Director, Center for Biotechnology. “It is exciting to witness our region’s innovators contemplating their research in ways they hadn’t before, and to see the vibrancy of the bioscience cluster on Long Island growing with each new project proposed.”
“Putting CSHL scientists together with HUB biotech entrepreneurs and industry reviewers is key to the successful translation of early stage ideas resulting from the basic research of Dr. Lingbo Zhang and Mickey Atwal, said Teri Willey, CSHL Vice President Business Development and Technology Transfer. “Zhang’s genetic research on myelodysplastic syndrome will be complimented by experience in medicinal chemistry. Similarly, Atwal’s work on developing therapeutics using physics and math to profile to the immune system will benefit from industry reviewers to guide it toward patient benefit."
“The success of the Long Island Bioscience Hub demonstrates the value of creative partnerships in bringing medical solutions that help address patients’ needs from the research lab to the doctor’s office and the medical clinic. We are proud to be part of the Bioscience Hub’s success,” said Kevin J. Tracey, M.D., President and CEO of the Feinstein Institute.
The main goal of the LIBH is to foster the development of therapeutics, preventatives, diagnostics, devices and research tools emerging from LIBH partner institutions that address diseases within the NIH’s mission.
Download a PDF of the press release here.
[post_title] => Long Island Bioscience Hub Announces Additional Funded Projects
[post_excerpt] => The Long Island Bioscience Hub (LIBH), has announced funding for ten projects totaling $550,000 under the Hub’s technology development and commercialization initiative.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => long-island-bioscience-hub-announces-additional-funded-projects
[to_ping] =>
[pinged] =>
[post_modified] => 2017-01-09 15:08:10
[post_modified_gmt] => 2017-01-09 15:08:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2499
[menu_order] => 156
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 3592
[post_author] => 3
[post_date] => 2020-07-24 11:40:47
[post_date_gmt] => 2020-07-24 11:40:47
[post_content] => The RADx Tech initiative aims to speed the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improve clinical laboratory tests, that can directly detect the virus. RADx Tech will expand the Point-of-Care Technologies Research Network (POCTRN) established several years ago by NIH’s National Institute of Biomedical Imaging and Bioengineering (NIBIB).
All scientists and inventors with a rapid testing technology are invited to compete in a national “shark tank”-type COVID-19 testing challenge for a share of up to $500 million over all phases of development. The technologies will go through a highly competitive, rapid three-phase selection process to identify the best candidates for at-home or point-of-care tests for COVID-19. Finalists will be matched with technical, business, and manufacturing experts to increase the odds of success.
Applications will be accepted on a rolling basis. Visit program website for full details on the RADx Programs and application process. https://www.nih.gov/research-training/medical-research-initiatives/radx/radx-programs
[post_title] => Update: NIH Rapid Acceleration of Diagnostics (RADx) Programs
[post_excerpt] => Scientists and inventors with a COVID-19 rapid testing technology: RADx Tech initiative challenge awarding shares of up to $500 million over all phases of development.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => update-nih-rapid-acceleration-of-diagnostics-radx-programs
[to_ping] =>
[pinged] =>
[post_modified] => 2024-12-03 14:59:29
[post_modified_gmt] => 2024-12-03 19:59:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3592
[menu_order] => 59
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 3428
[post_author] => 3
[post_date] => 2020-01-22 14:42:19
[post_date_gmt] => 2020-01-22 14:42:19
[post_content] => IO360˚ convenes stakeholders spanning the science and business communities to report on the latest data impacting immuno-oncology to fight a wider range of cancers. The 6th annual Immuno-Oncology 360° Summit is the premier meeting across all stakeholders in IO, addressing the rapid advancements of clinical, scientific and business developments of IO in one setting to help develop therapeutics for a wider range of cancers at an accelerated rate.
The 3 day summit features more than 80 time sensitive IO topics, over 500 senior level thought leaders and includes over 10 hours of networking. Use the code CFB20 for a 20% discount. For more information please visit:
www.io360summit.com
[post_title] => Immuno-Oncology 360˚ - February 26-28, 2020
[post_excerpt] => IO360˚addresses the rapid advancements of clinical, scientific and business developments of IO. Discount registration available for CFB constituents.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => immuno-oncology-360%cb%9a-february-26-28-2020
[to_ping] =>
[pinged] =>
[post_modified] => 2020-01-22 14:42:19
[post_modified_gmt] => 2020-01-22 14:42:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3428
[menu_order] => 77
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2024-12-05 11:35:07
[post_modified_gmt] => 2024-12-05 16:35:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 256
[max_num_pages] => 86
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)